Tasly Pharmaceutical Group Co. Ltd. A | Cash Flow
Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,166
1,450
1,524
1,219
1,402
1,592
Depreciation, Depletion & Amortization
206
263
315
338
372
392
Other Funds
884
830
740
223
434
550
Funds from Operations
1,534
1,930
2,114
1,766
2,202
2,518
Changes in Working Capital
1,188
1,317
1,771
609
3,003
951
Net Operating Cash Flow
346
613
344
1,157
801
1,567
Capital Expenditures
664
755
738
525
512
Sale of Fixed Assets & Businesses
57
31
149
17
24
Purchase/Sale of Investments
108
51
378
167
794
Net Investing Cash Flow
766
573
919
802
1,338
Cash Dividends Paid - Total
103
361
421
454
605
Issuance/Reduction of Debt, Net
1,306
1,272
28
590
3,400
Net Financing Cash Flow
321
81
290
87
2,361
Net Change in Cash
100
121
286
267
220
Free Cash Flow
317
141
394
632
1,312
Deferred Taxes & Investment Tax Credit
19
13
5
4
12
15
Net Assets from Acquisitions
111
2
-
182
25
Other Sources
78
103
49
58
30
Change in Capital Stock
2
-
-
-
-
Exchange Rate Effect
1
-
1
1
2
About Tasly Pharmaceutical Group Co.
View Profile
